Physician profile
Danny D Wester
NPI 1275890741
$1,660.16
in general payments reported to CMS, 2019-2025
15 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $532 · 2023: $202 · 2024: $192 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.43 | 2021-2025 | |
| Novo Nordisk INC | $298.85 | 2021-2025 | Wegovy |
| Axsome Therapeutics, INC. | $105.34 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $87.28 | 2021-2022 | |
| Lilly USA, LLC | $65.42 | 2021-2025 | Zepbound, Mounjaro |
| Ardelyx, INC. | $61.86 | 2025 | Ibsrela |
| Dexcom, INC. | $46.96 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $38.62 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $38.60 | 2021-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $38.55 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $35.69 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $31.65 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.14 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $16.48 | 2025 | |
| Seqirus USA INC | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Wester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.